Company Overview
Treace Medical Concepts, Inc. operates as a specialized medical technology company dedicated to the design, manufacturing, and marketing of medical devices within the United States, with a specific focus on the Lapiplasty System that enables surgeons to correct all three dimensions of bunion deformity and stabilize the first TMT joint. The firm functions within the broader Healthcare sector, specifically targeting the Medical Devices industry, where its product offerings are intended to facilitate patient recovery and allow for a return to weight-bearing activities. This entity maintains a substantial operational footprint supported by a workforce of 450 employees, generating a total annual revenue of $212.69 million over the trailing twelve-month period. With a market capitalization of $78.80 million, the company's valuation reflects a small-cap status that is consistent with its revenue generation relative to the number of staff, indicating a mid-sized player in a niche segment of orthopedic innovation.
Financial Health
The company reported a revenue of $212.69 million for the trailing twelve months, yet this top-line figure contrasts sharply with a net income of $-59,002,000 and an EBITDA of $-44,531,000. The significant gap between the $212.69 million in revenue and the $-59,002,000 in net income reveals a cost structure where operating expenses and other charges substantially exceed gross profit, resulting in a profit margin of -27.7%. Additionally, the EBITDA metric of $-44,531,000 further highlights that the company is currently operating without positive earnings power from its core business activities. Free cash flow stands at $-10,086,250, which indicates that the company is burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility for expansion or debt repayment without external capital injections. The gross margin is reported at 79.8%, suggesting that the core cost of goods sold is well-managed relative to sales, while the operating margin of -9.5% and profit margin of -27.7% demonstrate that overhead costs and non-operating expenses are eroding profitability. On the balance sheet, the company holds $48.37 million in cash against $71.86 million in debt, resulting in a debt-to-equity ratio of 82.29, which characterizes the balance sheet as highly leveraged given the negative equity environment. Despite the high leverage, the current ratio of 4.31 indicates a strong position regarding short-term liquidity, suggesting the firm can comfortably meet its current obligations. Return on Equity is -58.9% and Return on Assets is -16.6%, metrics that collectively reveal that management is currently unable to generate positive returns on the capital invested in the business or the assets utilized to generate revenue.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is calculated at -1.36, a metric that implies the market is pricing in expectations of negative earnings or a re-rating of the company's profitability trajectory. The price-to-book ratio stands at 0.89, indicating that the market values the company at less than its net book value, which often suggests a lack of market premium over book value or potential undervaluation relative to asset holdings. Alternative valuation metrics such as the price-to-sales ratio of 0.37 and an EV/EBITDA of -2.29 provide context for valuation in the absence of traditional earnings multiples, suggesting the stock is priced at a significant discount relative to its revenue base. In terms of trading range, the 52-week high is $8.87 and the 52-week low is $1.22, meaning the current share price sits at a level that reflects a wide volatility range within this specific period. The beta value of 0.77 indicates that the stock's price volatility is lower than the broader market, suggesting the asset may move less aggressively than the overall market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at -9.0%, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period. The negative revenue growth rate implies a contraction in the business scale, whereas the lack of positive earnings growth further underscores the challenges in expanding profitability within the current fiscal environment. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that the firm retains all available cash flow rather than distributing it to shareholders. This non-dividend profile suggests the company prioritizes reinvesting earnings into growth initiatives or covering operational losses rather than providing income to investors. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend payouts, reflecting a company in a development or restructuring phase that relies on external financing rather than internal cash generation.